Development of PLGA-lipid nanoparticles with covalently conjugated indocyanine green as a versatile nanoplatform for tumor-targeted imaging and drug delivery

Xin, Yu; Li, Shipeng; Yang, Chenlong

doi:10.2147/ijn.s119999

Cited by 38 publications

(41 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the basis of literature, the signal in Q2 + Q4 region in the representative dot plots are defined as apoptotic cells. 9 Cells treated with control and control + NIR showed few dead cells ( Figure 9E and F), while PTX-GHP-VEGF + NIR-treated cells showed a 91.2% apoptosis rate ( Figure 9H), which was higher than PTX-GHP-VEGF (42.8%) and free PTX (32.6%)-treated groups ( Figures 9G and S3). These findings suggest a significant synergistic cell killing effect of PTX-GHP-VEGF with NIR laser irradiation, which could be mainly ascribed to hyperthermia triggering more PTX release for enhanced chemotherapy.…”

mentioning

confidence: 95%

“…[5][6][7][8] In recent decades, natural antitumor drugs have been found to be effective against certain cancers such as resveratrol, curcumin, and artemisinin. [9][10][11][12][13] Paclitaxel (PTX) is a Food and Drug Administration-approved clinical tumor chemotherapeutic agent, which is a natural secondary metabolite purified from the bark of the gymnoside yew. 14,15 PTX is mostly used as treatment for ovarian and breast cancer.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Development of biocompatible and VEGF-targeted paclitaxel nanodrugs on albumin and graphene oxide dual-carrier for photothermal-triggered drug delivery in vitro and in vivo

Deng¹,

Qiu²,

Wang³

et al. 2018

IJN

View full text Add to dashboard Cite

In this study, we performed the characterization and synthesis of biocompatible and targeted albumin and graphene oxide (GO) dual-carrier paclitaxel (PTX) nanoparticles for photothermal-triggered tumor therapy. PTX absorbed on GO nanosheets as cores were coated with human serum albumin (HSA), following surface conjugation with monoclonal antibodies (mAb) against vascular endothelial growth factor (VEGF; denoted as mAbVEGF) via polyethylene glycol linker to form targeted nanoparticles (PTX-GHP-VEGF). The spherical nanoparticles were 191±5 nm in size with good stability and biocompatibility. GO functioned as the first carrier and a near infrared absorber that can generate photothermal effects under 5-minute 808-nm laser irradiation to thermal trigger the release of PTX from the second carrier HSA nanoparticles. The mechanism of thermal-triggered drug release was also investigated preliminarily, in which the heat generated by GO induced swelling of PTX-GHP-VEGF nanoparticles which released the drugs. In vitro studies found that PTX-GHP-VEGF can efficiently target human SW-13 adrenocortical carcinoma cells as evaluated by confocal fluorescence microscopy as well as transmission electron microscopy, and showed an obvious thermal-triggered antitumor effect, mediated by apoptosis. Moreover, PTX-GHP-VEGF combined with near infrared irradiation showed specific tumor suppression effects with high survival rate after 100 days of treatment. PTX-GHP-VEGF also demonstrated high biosafety with no adverse effects on normal tissues and organs. These results highlight the remarkable potential of PTX-GHP-VEGF in photothermal controllable tumor treatment.

show abstract

mentioning

confidence: 95%

Section: Introductionmentioning

confidence: 99%

Development of biocompatible and VEGF-targeted paclitaxel nanodrugs on albumin and graphene oxide dual-carrier for photothermal-triggered drug delivery in vitro and in vivo

Deng¹,

Qiu²,

Wang³

et al. 2018

IJN

View full text Add to dashboard Cite

show abstract

“…ICG, which is also referred to as Cardio Green, is a commonly clinically used NIR fluorophore (Alander et al, 2012). (Xin et al, 2016). (Xin et al, 2016).…”

Section: Photodynamic Therapy Approach With Nir Dyesmentioning

confidence: 99%

Near‐infrared imaging of diseases: A nanocarrier approach

Silindir-Gunay

Sarcan

Özer

2019

Drug Development Research

View full text Add to dashboard Cite

Developments in fluorescence imaging, brought popularity to near infrared (NIR) imaging with farred and NIR fluorophores applied for biosensing and bioimaging in living systems. Noninvasive NIR imaging gained popularity with the use of effective NIR dyes to obtain macroscopic fluorescence images. Several attributes of NIR dyes make them desirable agents, including high specificity, high sensitivity, minimized background interference, and the ability to easily conjugate with drug delivery systems. However, NIR dyes have some drawbacks and limitations, such as low solubility, low stability, and degradation. To overcome these issues, NIR dyes can be encapsulated in appropriate nanocarriers to achieve effective diagnosis, imaging, and therapy monitoring during surgery. Moreover, the vast majority of NIR dyes have photosensitizer features that can effectuate cancer treatment referred to as photodynamic therapy (PDT). In the near future, by combining NIR dyes with appropriate nanocarriers such as liposomes, polymeric micelles, polymeric nanoparticles, dendrimers, quantum dots, carbon nanotubes, or ceramic/silica based nanoparticles, the limitations of NIR dyes can be minimized or even effectively eliminated to form potential effective agents for imaging, therapy, and therapy monitoring of several diseases, particularly cancer. K E Y W O R D Scancer imaging, effective imaging, nanocarriers, near infrared dyes, near infrared imaging, photodynamic therapy, photosensitizers

show abstract

“…Also, these imaging methods can be useful for a better understanding of action mechanisms for various nanodelivery systems tested in preclinical tests, not only for diagnostic purposes. 53,54 Therefore, at present a wider range of imaging methods is available that can be implemented also in oral cancer, leading to improved diagnosis and an increased survival rate. 53 These are represented by positron-emission tomography (PET), single-photon-emission computed tomography (SPECT)/ CT, magnetic resonance imaging, fluorescence and bioluminescence scanning, and photoacoustic methods.…”

mentioning

confidence: 99%

“…53 These are represented by positron-emission tomography (PET), single-photon-emission computed tomography (SPECT)/ CT, magnetic resonance imaging, fluorescence and bioluminescence scanning, and photoacoustic methods. 54 In PET imaging, NPs can be functionalized with an isotope, 18 F, which decays by positron emission, meaning that the atomic nucleus emits protons that will combine with electrons, 55 while in SPECT γ-radiation is measured. 56 NPs can be conjugated with 125 …”

mentioning

confidence: 99%

Future trends and emerging issues for nanodelivery systems in oral and oropharyngeal cancer

Irimie

Sonea²,

Jurj

et al. 2017

IJN

View full text Add to dashboard Cite

Oral cancer is a prevalent cancer type on a global scale, whose traditional treatment strategies have several drawbacks that could in the near future be overcome through the development of novel therapeutic and prognostic strategies. Nanotechnology provides an alternative to traditional therapy that leads to enhanced efficiency and less toxicity. Various nanosystems have been developed for the treatment of oral cancer, including polymeric, metallic, and lipid-based formulations that incorporate chemotherapeutics, natural compounds, siRNA, or other molecules. This review summarizes the main benefits of using these nanosystems, in parallel with a particular focus on the issues encountered in medical practice. These novel strategies have provided encouraging results in both in vitro and in vivo studies, but few have entered clinical trials. The use of nanosystems in oral cancer has the potential of becoming a valid therapeutic option for patients suffering from this malignancy, considering that clinical trials have already been completed and others are currently being developed.

show abstract

Development of PLGA-lipid nanoparticles with covalently conjugated indocyanine green as a versatile nanoplatform for tumor-targeted imaging and drug delivery

Cited by 38 publications

References 53 publications

Development of biocompatible and VEGF-targeted paclitaxel nanodrugs on albumin and graphene oxide dual-carrier for photothermal-triggered drug delivery in vitro and in vivo

Development of biocompatible and VEGF-targeted paclitaxel nanodrugs on albumin and graphene oxide dual-carrier for photothermal-triggered drug delivery in vitro and in vivo

Near‐infrared imaging of diseases: A nanocarrier approach

Future trends and emerging issues for nanodelivery systems in oral and oropharyngeal cancer

Contact Info

Product

Resources

About